ijms-logo

Journal Browser

Journal Browser

Immune Evasion and Pathological Prognostic Biomarkers in Bladder Cancer

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 20 December 2024 | Viewed by 2370

Special Issue Editors


E-Mail Website
Guest Editor
Department of Biological Science, Dong-A University, Busan 49315, Republic of Korea
Interests: bladder cancer; hepatocellular carcinoma; colorectal cancer
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Biomedical Sciences, College of Natural Science, Dong-A University, Busan, Republic of Korea
Interests: immune regulation; regulatory cells; innate lymphoid cells; allergy; atopic dermatitis; rheumatoid arthritis; autoimmune diseases; immune evasion

Special Issue Information

Dear Colleagues,

Bladder cancer is a prevalent malignant condition worldwide, and its mortality rates vary depending on the subtype. Non-muscle invasive tumors that grow on the inner surface of the bladder generally have a better prognosis, whereas muscle-invasive or metastatic bladder cancer poses significant challenges and leads to poor patient outcomes. In the case of non-muscle invasive bladder cancer (NMIBC), especially in high-risk groups, numerous studies have investigated the prognosis of the immune response in combination with early-age Bacillus Calmette-Guérin (BCG) treatment. Recent advances in cancer biology and immunology have shed light on the complex interaction between the tumor microenvironment and the immune system of the host, specifically in the context of bladder cancer.

Within the tumor microenvironment, immune molecules and cells display a complex and ambivalent nature, influencing the delicate equilibrium between tumor elimination and the suppression of antitumor immune responses. Therefore, it is crucial to elucidate prognostic immunological molecular biomarkers associated with tumor progression and decipher the mechanisms underlying immune evasion and tumor-mediated immunosuppression. These efforts are pivotal in optimizing prognosis and developing effective treatment strategies.

Given the clinical significance of bladder cancer, the objective of this Special Issue, titled "Immune Evasion and Pathological Prognostic Biomarkers in Bladder Cancer", is to unravel and target pertinent biomarkers within the tumor microenvironment that have potential in immunological diagnosis, prognostication, and understanding immune evasion mechanisms. Bladder cancer is characterized by a high recurrence rate and sensitivity to anticancer drugs, underscoring the urgency to generate contemporary research findings and evidence-based recommendations to enhance treatment modalities.

By addressing these aforementioned aspects, this Special Issue aims to provide an updated and comprehensive understanding of the immunological landscape of bladder cancer, ultimately facilitating the development of personalized therapeutic approaches and improving patient outcomes.

We have already run a number of Special Issues; see:

https://www.mdpi.com/journal/ijms/special_issues

Dr. Sun-Hee Leem
Dr. Hyuk Soon Kim
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bladder cancer
  • immune evasion
  • tumor microenvironment
  • tumor prognosis
  • immune checkpoint
  • immune tolerance

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

20 pages, 2224 KiB  
Review
Strategies for Overcoming Immune Evasion in Bladder Cancer
by Juhyun Shin, Jeong Won Park, Seon Young Kim, Jun Ho Lee, Wahn Soo Choi and Hyuk Soon Kim
Int. J. Mol. Sci. 2024, 25(6), 3105; https://doi.org/10.3390/ijms25063105 - 7 Mar 2024
Cited by 1 | Viewed by 1952
Abstract
Tumors intricately shape a highly immunosuppressive microenvironment, hampering effective antitumor immune responses through diverse mechanisms. Consequently, achieving optimal efficacy in cancer immunotherapy necessitates the reorganization of the tumor microenvironment and restoration of immune responses. Bladder cancer, ranking as the second most prevalent malignant [...] Read more.
Tumors intricately shape a highly immunosuppressive microenvironment, hampering effective antitumor immune responses through diverse mechanisms. Consequently, achieving optimal efficacy in cancer immunotherapy necessitates the reorganization of the tumor microenvironment and restoration of immune responses. Bladder cancer, ranking as the second most prevalent malignant tumor of the urinary tract, presents a formidable challenge. Immunotherapeutic interventions including intravesical BCG and immune checkpoint inhibitors such as atezolizumab, avelumab, and pembrolizumab have been implemented. However, a substantial unmet need persists as a majority of bladder cancer patients across all stages do not respond adequately to immunotherapy. Bladder cancer establishes a microenvironment that can actively hinder an efficient anti-tumor immune response. A deeper understanding of immune evasion mechanisms in bladder cancer will aid in suppressing recurrence and identifying viable therapeutic targets. This review seeks to elucidate mechanisms of immune evasion specific to bladder cancer and explore novel pathways and molecular targets that might circumvent resistance to immunotherapy. Full article
Show Figures

Figure 1

Back to TopTop